STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Esperion Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Esperion Therapeutics (ESPR) Form 144 notice: The filer reports a proposed sale of 6,267 common shares with an aggregate market value of $17,575.80, to be sold through Fidelity Brokerage Services LLC on or about 09/17/2025 on the NASDAQ. The shares were acquired on 09/15/2025 by restricted stock vesting from the issuer and were paid as compensation. The filing also discloses sales by the same person in the prior three months: 6,422 shares sold on 06/17/2025 for $7,397.50 and 1,304 shares sold on 07/17/2025 for $1,469.35. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information.

Positive

  • Full compliance with Rule 144 disclosure requirements including broker, acquisition details, and prior three-month sales
  • Clear attribution of shares as restricted stock vesting and payment as compensation, providing transparency on origin of securities

Negative

  • Insider selling activity disclosed: proposed sale of 6,267 shares and prior sales totaling 7,726 shares in the past three months

Insights

TL;DR: Insider proposes to sell 6,267 newly vested restricted shares; prior small sales occurred in June and July.

The filing documents a proposed sale of 6,267 common shares acquired by restricted stock vesting on 09/15/2025 with an aggregate market value of $17,575.80, to be executed via Fidelity on or about 09/17/2025. The filer also reported two prior sales in the last three months totaling 7,726 shares with combined gross proceeds of $8,866.85. All details presented are transactional: acquisition method is explicitly listed as restricted stock vesting and payment as compensation. No financial results, forward guidance, or other issuer-level metrics are included in this notice.

TL;DR: Routine Rule 144 disclosure of vested equity being offered for sale; contains required seller attestation.

The notice fulfills Rule 144 reporting by identifying the class, quantity, acquisition date, acquisition nature (restricted stock vesting), broker, and approximate sale date. It includes the seller's attestation regarding material nonpublic information and a signature block warning about false statements. The filing is procedural and does not disclose any additional governance actions or extraordinary transactions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Esperion (ESPR) Form 144 disclose?

The notice discloses a proposed sale of 6,267 common shares (aggregate market value $17,575.80) to be sold via Fidelity on or about 09/17/2025.

How were the 6,267 ESPR shares acquired?

The shares were acquired on 09/15/2025 through restricted stock vesting from the issuer and the consideration is listed as compensation.

Were there any recent ESPR share sales by the same person?

Yes. The filer reported selling 6,422 shares on 06/17/2025 for $7,397.50 and 1,304 shares on 07/17/2025 for $1,469.35.

Through which broker will the ESPR shares be sold?

The broker listed is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI, and the exchange is the NASDAQ.

Does the filing state any undisclosed material information about Esperion?

The seller represents by signature that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.
Esperion Therape

NASDAQ:ESPR

ESPR Rankings

ESPR Latest News

ESPR Latest SEC Filings

ESPR Stock Data

730.17M
235.80M
0.56%
50.62%
11.08%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ANN ARBOR